News und Analysen
Valbiotis gibt Unterzeichnung einer Forschungspartnerschaft zur intestinalen Mikrobiota mit der MEDIS-Einheit der Universität Clermont Auvergne bekannt
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA-SME-qualifiziertes Unternehmen), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur
Valbiotis Announces the Signature of a Research Partnership in Intestinal Microbiota With the MEDIS Unit From the Clermont Auvergne University
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
EQS-News: Abivax to attend the J.P. Morgan 41st Annual Healthcare Conference
EQS-News: Heidelberg Pharma AG: Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG ("Vifor") announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining
Evolva launches its Natural Nootkatone
Relief Therapeutics to Participate in January Investor Meetings
Cosmo announces successful Phase III clinical trial of Lumeblue™ in China
LivaNova Announces Receipt of Close-Out of Warning Letter from U.S. Food and Drug Administration
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received a close-out letter from the U.S. Food and Drug Administration (FDA) for the
Inogen to Present at 41st Annual J.P. Morgan Healthcare Conference
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the company will be participating in the
ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been recognised with a number of coveted business and industry awards over the second half
IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split
IMV Inc. (the “Corporation” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) has announced the U.S. Food and Drug Administration (FDA) approval of its therascreen® KRAS RGQ PCR kit (therascreen KRAS kit) as a companion
Therapie für nicht-kleinzelliges Lungenkarzinom: QIAGEN erhält FDA-Zulassung für Begleitdiagnostikum zu KRAZATI von Mirati Therapeutics
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat von der US-amerikanischen Arzneimittelzulassungsbehörde FDA die Zulassung des therascreen® KRAS RGQ PCR-Kits (therascreen KRAS-Kit) als
Relief Therapeutics Announces Issuance of Shares from Authorized Capital
Agilent Resolution ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer
Agilent Technologies Inc. (NYSE: A) announced today that the U.S. Food and Drug Administration (FDA) has approved Agilent Resolution ctDx FIRST as a companion diagnostic (CDx) to identify advanced
QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho” or the “Company”), a global provider of innovative in vitro diagnostic (IVD) technologies designed for point-of-care settings, clinical labs
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286
Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe
Evolva statement to SER communication
Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial
Pfizer Inc. (NYSE:PFE) today announced 10.4 month follow-up data from the pivotal Phase 2 MagnetisMM-3 clinical trial suggesting elranatamab, a B-cell maturation antigen (BCMA)-CD3-targeted
Pfizer Declares First-Quarter 2023 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.41 for the first-quarter 2023 dividend